# Study to Evaluate the Effect of Bimosiamose on Ozone Induced Sputum Neutrophilia

> **NCT00962481** · PHASE2 · COMPLETED · sponsor: **Revotar Biopharmaceuticals AG** · enrollment: 18 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Bimosiamose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00962481
- **Lead sponsor:** Revotar Biopharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2010-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00962481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00962481, "Study to Evaluate the Effect of Bimosiamose on Ozone Induced Sputum Neutrophilia". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00962481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*